Survodutide vs AHK-Cu
Side-by-side comparison of key properties, dosing, and research.
GLP-1 / Weight Loss Agonists
SurvodutideSkin & CosmeticAnti-Aging & Longevity
AHK-Cu- Summary
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- AHK-Cu is a copper tripeptide composed of alanine, histidine, and lysine chelated to copper. Distinct from GHK-Cu, AHK-Cu exhibits strong affinity for hair follicle receptors and demonstrates potent hair growth stimulation alongside wound healing and skin regeneration properties.
- Half-Life
- ~7 days
- Hours (topical, variable by formulation)
- Admin Route
- SubQ
- Topical, Scalp application, Subcutaneous (research)
- Research
- —
- —
- Typical Dose
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- 0.01–0.1% concentration
- Frequency
- Once weekly
- Once or twice daily
- Key Benefits
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Stimulates hair follicle growth and reduces shedding
- Increases dermal papilla cell proliferation
- Promotes wound healing and skin regeneration
- Antioxidant protection via superoxide dismutase activation
- Improves skin elasticity and firmness
- Supports collagen and elastin production
- Side Effects
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Generally well-tolerated topically
- Mild scalp irritation or redness in sensitive individuals
- Possible temporary hair shedding phase at treatment initiation
- Copper accumulation with excessive systemic use (rare)
- Stacks With
- —
- —